Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    regeneron | birch allergy
Previous Study | Return to List | Next Study

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04709575
Recruitment Status : Recruiting
First Posted : January 14, 2021
Last Update Posted : February 16, 2021
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:
The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Conjunctivitis Drug: REGN5713 Drug: REGN5714 Drug: REGN5715 Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis
Actual Study Start Date : January 14, 2021
Estimated Primary Completion Date : August 30, 2021
Estimated Study Completion Date : August 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hay Fever

Arm Intervention/treatment
Experimental: REGN5713-5714-5715
REGN5713-5714-5715 administered subcutaneously
Drug: REGN5713
Administered subcutaneously

Drug: REGN5714
Administered subcutaneously

Drug: REGN5715
Administered subcutaneously

Placebo Comparator: Placebo Only
Placebo matching REGN5713-5714-5715 administered subcutaneously
Drug: Placebo
Placebo that replaces REGN5713-5714-5715




Primary Outcome Measures :
  1. Combined symptom and medication score (CSMS) in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Until the end of Birch Pollen Season, up to Week 16 ]
    CSMS is calculated by adding the Daily Medication Score (DMS) and Total Symptom Score (TSS) together, with scores ranging between 0 (none) and 38 (severe).


Secondary Outcome Measures :
  1. Total symptom score (TSS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Until the end of Birch Pollen Season, up to Week 16 ]
    TSS is a combined score of TOSS and TNSS. TNSS and TOSS are scored as in part 1 each for a combined TSS of 0 (none) to 18 (severe)

  2. Total nasal symptom score (TNSS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Until the end of Birch Pollen Season, up to Week 16 ]
    Total nasal symptom score (TNSS) is from 0 to 12 and is based on assessment of 4 nasal symptoms graded on a Likert scale ranging from 0 (none) to 3 (severe) for congestion, itching, and rhinorrhea, and from 0 (none) to 3 (5 or more sneezes) for sneezing.

  3. Total ocular symptom score (TOSS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Until the end of Birch Pollen Season, up to Week 16 ]
    Total ocular symptom score is 0 to 6 and is based on itching/redness/gritty feeling and tearing/watering; each of the 2 symptoms is graded 0 (absent), 1 (mild), 2 (moderate), and 3 (severe)

  4. Daily medication score (DMS), averaged over the duration of the birch pollen season, in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Until the end of Birch Pollen Season, up to Week 16 ]
    The Daily Medication Score (DMS) is calculated by adding points for each pre-specified medication taken as follows: desloratadine 5 mg 6 points/dose; maximum daily score 6 points, olopatadine 1 mg/mL each drop 1.5 points/drop; maximum daily score 6 points, mometasone furoate 50 ug/dose 2.0 points/spray; maximum daily score 8 points). The scale is 0 (minimum) to 20 (maximum)

  5. Incidence of Treatment-Emergent Adverse Events (TEAEs) throughout the study [ Time Frame: Up to Day 127 ]
  6. Incidence of Serious TEAEs throughout the study [ Time Frame: Up to Day 127 ]
  7. Change from baseline to the end of study in birch SPT mean wheal diameter in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Baseline through Day 127 ]
  8. Percent change from baseline to the end of study in birch SPT mean wheal diameter in participants who receive a single dose of REGN5713-5714-5715 versus placebo [ Time Frame: Baseline through Day 127 ]
  9. Serum concentration of REGN5713 over the study duration [ Time Frame: Up to Day 127 ]
  10. Serum concentration of REGN5714 over the study duration [ Time Frame: Up to Day 127 ]
  11. Serum concentration of REGN5715 over the study duration [ Time Frame: Up to Day 127 ]
  12. Incidence of treatment emergent anti-drug antibodies to REGN5713 throughout the study [ Time Frame: Up to Day 127 ]
  13. Incidence of treatment emergent anti-drug antibodies to REGN5714 throughout the study [ Time Frame: Up to Day 127 ]
  14. Incidence of treatment emergent anti-drug antibodies to REGN5715 throughout the study [ Time Frame: Up to Day 127 ]
  15. Number of "Well Days" [ Time Frame: Until the end of Birch Pollen Season, up to Week 16 ]
    "Well Days" are defined as days when rescue medication is not utilized and the Total symptom score (TSS) is ≤2/18



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria

  1. Documented or participant-reported history of birch pollen-triggered allergic rhinitis symptoms, with or without conjunctivitis, for at least 2 years
  2. Positive Skin prick test (SPT) with birch pollen extract in the screening period, as defined in the protocol
  3. Positive Allergen-specific IgE (sIgE) tests for birch pollen and Bet v 1 in the screening period, as defined in the protocol
  4. Willing and able to comply with clinic visits and study-related procedures

Key Exclusion Criteria:

  1. Participation in a prior REGN5713-5714-5715 clinical trial
  2. Recurrent or chronic rhinitis or sinusitis not associated with birch pollen season, or due to daily contact with other allergens causing symptoms that are expected to coincide with birch pollen season, as assessed by the investigator
  3. Participants who anticipate major changes in allergen exposure in their home or work environments that are expected to coincide with the study assessments as assessed by the investigator
  4. Persistent chronic or recurring acute infection requiring treatment with antibiotics, antivirals, or antifungals, or any untreated respiratory infections (at the discretion of the investigator) within 4 weeks prior to screening visit. Participants may be re-evaluated for eligibility after symptoms resolve
  5. Documentation of active SARS-CoV-2 infection, as defined in the protocol
  6. A clinical history of asthma with 2 or more asthma exacerbations requiring hospitalizations or systemic corticosteroids in the previous year
  7. History of birch allergy immunotherapy as defined in the protocol
  8. Use of anti-IgE or other biological therapy in treatment of asthma or allergy within 6 months prior to screening

NOTE: Other protocol defined Inclusion/Exclusion Criteria apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04709575


Contacts
Layout table for location contacts
Contact: Clinical Trials Administrator 844-734-6643 clinicaltrials@regeneron.com

Locations
Layout table for location information
United States, Pennsylvania
Regeneron Study Site Recruiting
Pittsburgh, Pennsylvania, United States, 15241
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
Layout table for additonal information
Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04709575    
Other Study ID Numbers: R5713-5714-5715-ALG-2001
2020-004094-52 ( EudraCT Number )
First Posted: January 14, 2021    Key Record Dates
Last Update Posted: February 16, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access Criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
URL: https://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Regeneron Pharmaceuticals:
Birch Allergy
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Rhinitis
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Conjunctivitis
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Immune System Diseases
Conjunctival Diseases
Eye Diseases